Granted Patent
B2
US 8,354,411 · App. 13/148,172 · Granted Jan 15, 2013
1-phenyl-3-pyrazolylpyridazin-4(1H)-one compound
Assignee:
Takeda Pharmaceutical Company Limited
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The present invention provides a compound which has the effect of PDE inhibition, and which is useful as a medicament for preventing or treating schizophrenia or so on. A compound of formula (I 0 ), wherein R1 represents a substituent; R2 represents a hydrogen atom, or a substituent; R3 represents a hydrogen atom, or a substituent; Ring A represents an aromatic ring which can be substituted, and Ring B represents a 5-membered heteroaromatic ring which can be substituted, or a salt thereof.
Claims (1)
1. 1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-5-methoxy-3-(1-phenyl-1H-pyrazol-5-yl)pyridazin-4(1H)-one, or a salt thereof.
Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded May 6, 2026
From: TAKEDA PHARMACEUTICAL COMPANY LIMITED
To: AXSOME THERAPEUTICS, INC.
Reel/Frame 075778/0924 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Oct 20, 2011
From: TANIGUCHI, TAKAHIKO; KAWADA, AKIRA; KONDO, MITSUYO; QUINN, JOHN F.; KUNITOMO, JUN; YOSHIKAWA, MASATO; FUSHIMI, MAKOTO
To: TAKEDA PHARMACEUTICAL COMPANY LIMITED
Reel/Frame 027092/0835 →
Continuity (3)
Provisional Application
61202207
· Feb 5, 2009
Provisional Application
61213927
· Jul 30, 2009